Influence of a 3-month letermovir treatment on inflammation, immunity and HIV reservoir markers in people with HIV on antiretroviral therapy (AIDS 2026) - May 3, 2026 - Abstract #WEPEB061; Pres time: Jul 29, 2026; 12:00 PM - 01:00 PM; Location: Poster Board Number 061; "CMV inhibition with letermovir was safe, reduced CMV-specific IgG and T-cell levels, and HIV transcriptional activity in PWH on ART, supporting the role of CMV replication in HIV persistence. A strategic CMV replication inhibition with letermovir could represent a novel adjunctive approach to improve the efficacy of vaccines and immunotherapies in PWH on ART."
IO biomarker • Cytomegalovirus Infection • Human Immunodeficiency Virus • Infectious Disease • Inflammation • CD4 • CD8
|
|
S. Isnard1,2; L. Royston1,2,3; T. Mabanga1,2; H. Traoré4; A. Pagliuzza4; C.A. Berini1,2; J. Girouard1,2; T. Bessissow1,5; P.L. Lakatos1,5; C.T. Costiniuk1,2; B. Lebouché1,2; R. Fromentin4; N. Chomont4; J.-P. Routy1,2,6
|